Legend Biotech's Q2 shows CARVYKTI sales hitting $710M and improving operating leverage. Find out why LEGN stock is a buy.

New Jersey-based Legend Biotech announced its Q2 earnings on Monday, reporting $439m of revenues for its only commercial product, the cell therapy Carvykti. Carvykti leads CAR-T therapy sales with ...

Identify investment targets, pipeline priorities, partnerships, and sector entry strategies through high-level regulatory, clinical, sales, and market-based analysis.Dublin, Oct. 20, 2026 (GLOBE ...

Danaher's third-quarter earnings beat estimates by 9.9%, driven by stronger Biotechnology profitability, while it raised its ...

Krystal Biotech KRYS reported first-quarter 2026 earnings per share (EPS) of $1.83, which surpassed the Zacks Consensus Estimate of $1.45. The reported EPS was up from $1.20 in the year-ago quarter.

Clever Culture Systems will expand its reach across the North American and Singapore pharmaceutical manufacturing markets ...

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those ...

Biotech stock Zai Lab (ZLAB) slipped as investors digested the company's mixed fourth-quarter earnings report early Thursday. The stock is approaching a buy point. Zai Lab — Thursday's pick for IBD 50 ...

Oncolytics Biotech (NASDAQ:ONCY) has established a new at-the-market equity financing agreement with BTIG, LLC. As disclosed in a Securities and Exchange Commission (SEC) filing on October 17, 2025, ...

The macroenvironment in 2025 looks grim as signs of a slowdown in the economy set in. The biotech industry experienced a choppy ride in 2024, and the same is likely in store in 2025. Given the ...

Stock sales from drug developers are off to a flying start on US exchanges in 2026, boosting the prospects for biotechnology fundraising after turbulence in the sector last year. Aided by a rebound in ...